Last Updated : June 30, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Omvoh | mirikizumab | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Onbrez | Indacaterol | Chronic obstructive pulmonary disease | List in a similar manner | Complete | ||
| Oncaspar | pegaspargase | Adult Acute Lymphocytic Leukemia (ALL) | Unable to recommend reimbursement | Not filed | ||
| Ondexxya | andexanet alfa | Reversal of FXa inhibitor anticoagulant effects | Do not reimburse | Complete | ||
| Onglyza | Saxagliptin | Diabetes mellitus, type 2 | List with criteria/condition | Complete | ||
| Onglyza | Saxagliptin | Diabetes mellitus, type 2 | Withdrawn | |||
| Onglyza | Saxagliptin | Diabetes mellitus (Type 2) | Do not list | Complete | ||
| Onivyde | Nanoliposomal Irinotecan | Cancelled | ||||
| Onivyde | Irinotecan Liposome | Metastatic Pancreatic Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Onpattro | patisiran | Polyneuropathy in hereditary transthyretin-mediated amyloidosis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Onsolis | Fentanyl Citrate | Pain, breakthrough cancer pain | Withdrawn | |||
| Onsolis | Fentanyl Citrate | Pain, breakthrough cancer pain | Do not list | Complete | ||
| Onstryv | safinamide | Parkinson's disease | Do not reimburse | Complete | ||
| Onureg | azacitidine | Acute myeloid leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Opdivo | Nivolumab | Melanoma Adjuvant Therapy | Reimburse with clinical criteria and/or conditions | Complete | ||
| Opdivo | Nivolumab | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Opdivo | Nivolumab | Metastatic non small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Opdivo | Nivolumab | Metastatic Renal Cell Carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Opdivo | Nivolumab | Squamous Cell Carcinoma of Head and Neck (SCCHN) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Opdivo | nivolumab | Stage IIB or IIC melanoma, adjuvant | Reimburse with clinical criteria and/or conditions | Active | ||
| Opdivo | nivolumab | Urothelial carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Opdivo | Nivolumab | classical Hodgkin Lymphoma (cHL) after failure of ASCT | Reimburse with clinical criteria and/or conditions | Complete | ||
| Opdivo | Nivolumab | Metastatic Hepatocellular Carcinoma (HCC) | Do not reimburse | Complete | ||
| Opdivo | nivolumab | Gastroesophageal junction or esophageal adenocarcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Opdivo | nivolumab | Esophageal or gastroesophageal junction cancer | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : June 30, 2024